Compare Mattel Inc (MAT) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mattel Inc vs Revvity Inc — how do they compare? Mattel Inc trades at $16.56 (market cap $4.74B), while Revvity Inc trades at $152.05 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 3.6× Mattel Inc's market cap, and Revvity Inc pays a 0.18% dividend while Mattel Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mattel Inc for 97 Days and Revvity Inc for 12 Days on average.
| MAT | RVTY | |
|---|---|---|
Market Cap | $4.74B | $16.98B |
Volume | 11,809,722 | 1,456,900 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.16 | $157.36 |
52-Week Low | $12.66 | $82.26 |
Typical Hold Time | 97 Days | 12 Days |
Enterprise Value | $6.96B | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mattel (MAT) trades at $16.37, up 2.76% amid takeover speculation, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings but maintains solid profitability with a 7.78% net income margin and a reasonable P/E of 12.22. Recent news highlights CEO transition and acquisition interest from Authentic Brands Group, potentially valuing the firm around $6 billion.
The stock's outlook is supported by strong analyst sentiment (52.94% buy ratings) and a stable financial base, though risks include earnings volatility and leadership changes. Near-term price action hinges on takeover developments and new CEO execution, with the consensus price target at $15.00 suggesting limited upside from current levels.
RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving average signals and has beaten earnings estimates for three consecutive quarters. Recent developments include the launch of a CE-IVDR-certified T1D screening kit in Europe (Business Wire, 2026-09-24) and the acquisition of Human Cell Design to expand metabolic disease research tools (Business Wire, 2026-09-09).
The outlook is positive, supported by earnings momentum, strategic acquisitions, and analyst optimism. However, the stock trades at a premium valuation with a P/E of 73.15, and near-term risks include margin pressures in China and rich valuation limiting upside beyond consensus targets. Revenue stability but slight profit margin compression in 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
